tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Intercept Pharma (ICPT) and Moderna (MRNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNYResearch Report), Intercept Pharma (ICPTResearch Report) and Moderna (MRNAResearch Report).

Alnylam Pharma (ALNY)

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Alnylam Pharma today and set a price target of $250.00. The company’s shares closed last Wednesday at $205.21, close to its 52-week high of $212.00.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 6.2% and a 40.4% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Arrowhead Pharmaceuticals, and Better Therapeutics, Inc.

Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $206.44, a -1.7% downside from current levels. In a report issued on July 28, RBC Capital also maintained a Buy rating on the stock with a $225.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Intercept Pharma (ICPT)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Intercept Pharma today and set a price target of $30.00. The company’s shares closed last Wednesday at $13.98.

According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -28.1% and a 21.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intercept Pharma with a $28.38 average price target, representing a 124.9% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $82.00 price target.

Moderna (MRNA)

Needham analyst Joseph Stringer maintained a Hold rating on Moderna today. The company’s shares closed last Wednesday at $188.68.

According to TipRanks.com, Stringer has 0 stars on 0-5 stars ranking scale with an average return of -12.6% and a 30.6% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Apellis Pharmaceuticals, and Lexicon Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $216.55 average price target, a 29.1% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Hold rating on the stock with a $165.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More